Curated News
By: NewsRamp Editorial Staff
August 14, 2024
Oncolytics Biotech's Pelareorep Shows Promise in Fighting Metastatic Breast Cancer
Discuss on Reddit
Discuss on SubstackTLDR
- Oncolytics Biotech's pelareorep has the potential to extend survival rates in metastatic breast cancer, giving a competitive edge in the treatment market.
- Pelareorep is an immunotherapeutic agent that induces anti-cancer immune responses, recruits and trains immune cells, and remodels the tumor microenvironment to enable immune cell access.
- The potential of pelareorep to extend survival rates in metastatic breast cancer represents a step towards addressing the high unmet medical needs of patients, making tomorrow better than today.
- Pelareorep has fast track designation from the FDA, aligning with key design elements and objectives for potential registration-enabling trial, showing promise in fighting metastatic breast cancer.
Impact - Why it Matters
Metastatic breast cancer is a serious and often fatal condition, and extending survival rates is crucial. Oncolytics Biotech's innovative treatment, pelareorep, has the potential to make a significant impact in the fight against this deadly disease.
Summary
One in eight women in the U.S. will face a breast cancer diagnosis, with one in three becoming metastatic. The metastatic breast cancer treatment market is projected to reach $41.74 billion by 2030. Oncolytics Biotech Inc. is at the forefront of this battle, with its immunotherapeutic agent, pelareorep, showing promising results in fighting challenging cancers, including metastatic breast cancer. Clinical trials have demonstrated meaningful improvements in overall response rate and progression-free survival, and the company has received fast track designation from the FDA.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Oncolytics Biotech's Pelareorep Shows Promise in Fighting Metastatic Breast Cancer
